Research & Development
The US Food and Drug Administration approves Regeneron and Sanofi's Dupixent
14 March 2019 -

The US Food and Drug Administration (FDA) has approved United States-based Regeneron Pharmaceuticals' and France-based Sanofi's Dupixent (dupilumab) for adolescent patients 12 to 17 years of age with moderate-to-severe atopic dermatitis, it was reported yesterday.

The product can be utilised with or without topical corticosteroids. It is a targeted biologic therapy that inhibits signalling of interleukin-4 (IL-4) and interleukin-13 (IL-13), two key proteins that are likely to play a central role in type two inflammation that underlies atopic dermatitis and several other allergic diseases. It was also granted Breakthrough Therapy designation by the US FDA for inadequately controlled moderate-to-severe atopic dermatitis in adolescents. The Breakthrough Therapy designation was created to accelerate the development and review of drugs developed for serious or life-threatening conditions.

The US FDA assessed the product application under Priority Review, which is reserved for medicines that represent potentially significant improvements in safety or efficacy in treating serious conditions.



Related Headlines